Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

51.4%

36 terminated/withdrawn out of 70 trials

Success Rate

41.9%

-44.7% vs industry average

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

162%

42 of 26 completed trials have results

Key Signals

3 recruiting42 with results31 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2
48(72.7%)
Phase 1
13(19.7%)
N/A
2(3.0%)
Phase 3
2(3.0%)
Early Phase 1
1(1.5%)
66Total
Phase 2(48)
Phase 1(13)
N/A(2)
Phase 3(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (70)

Showing 20 of 70 trials
NCT05583708Phase 2Recruiting

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Role: collaborator

NCT03317158Phase 1Active Not Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Role: collaborator

NCT04848337Phase 2Active Not Recruiting

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Role: collaborator

NCT05956041Phase 2Recruiting

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Role: collaborator

NCT03971409Phase 2Active Not Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Role: collaborator

NCT04858256Phase 2Recruiting

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Role: collaborator

NCT03547999Phase 2Terminated

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Role: collaborator

NCT03117309Phase 2Completed

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Role: collaborator

NCT02365766Phase 1Completed

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Role: collaborator

NCT03272217Phase 2Terminated

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Role: collaborator

NCT02581215Phase 2Completed

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Role: collaborator

NCT01074970Phase 2Completed

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Role: lead

NCT02581059Phase 2Terminated

Efficacy of Ginseng for Patients on Regorafenib

Role: collaborator

NCT03451331Phase 2Completed

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Role: collaborator

NCT03396471Phase 2Terminated

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Role: lead

NCT01215136Phase 2Terminated

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Role: collaborator

NCT01177683Phase 1Terminated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Role: collaborator

NCT02643043Not ApplicableCompleted

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch

Role: collaborator

NCT02101385Phase 2Completed

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Role: collaborator

NCT02343952Phase 2Completed

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Role: collaborator